Empowering Biologics
with Generative AI
About Us
We are an AI-driven company dedicated to transforming the biologics manufacturing industry, such as the production of antibodies, proteins, mRNA, cell & gene therapies, etc. Our mission is to improve patients' access to the most innovative biologics, starting with the pressing challenges in R&D and manufacturing.
ChemT’s proprietary AI-driven cellular drug discovery (AICD) platform is the core of our innovation. Leveraging cutting-edge artificial intelligence, we design and deliver small molecules to make biologics production more robust and scalable. By optimizing the yield and efficacy of biologic treatments, our platform offers a new approach to improving the performance and accessibility of life-changing therapies.
Our flagship asset, Chemplify™ , is now commercially available for the T cell therapeutic manufacturing. As a formulated anti-senescent solution containing patented small molecules, Chemplify™ achieves 5-10x higher T cell yield with significantly enhanced quality. Its proven in vitro and in vivo efficacy sets a new industry benchmark, enabling more effective and scalable immunotherapies for cancer.
Our vision goes beyond a single compound. We strive to replace traditional components like human serum and cytokines with small-molecule solutions that establish a chemically defined, consistent, and high-quality culture environment. Beyond T cells, our research and development pipeline focuses on optimizing CHO cells and advancing AAV generation, further amplifying the reach of our AI-driven biotech innovations. This transformation not only enhances consistency and reliability but also significantly boosts the scalability of biologics manufacturing.
Our Team
Our team includes world-leading experts in molecular biology, medicinal chemistry and artificial intelligence from several research institutions including the Harvard University, Stanford University, National University of Singapore, Karolinska Institute, and University College London, and with ample industry experiences from Johnson & Johnson, BeiGene, and AstraZeneca. Our team members bring extensive industry experience from companies such as Johnson & Johnson, BeiGene, and AstraZeneca, ensuring a seamless integration of scientific excellence with industry innovation.
Ling Wu, PhD
President & Co-Founder
Jie Sun
CEO & Co-Founder
Prof. Nicholas Gascoigne
Scientific Advisor & Co-Founder
Hancheng Zhang, PhD
Strategic Partner
Science
We leverage advanced AI models through our proprietary platform, enabling rapid identification and development of small molecules with targeted biological effects. Using this platform, we create precise screening models to discover targets whose modulation—whether through antagonism or agonism—enhances T cell expansion and improves product quality, potentially without the need for serum or cytokines.
Our flagship product, Chemplify, is a small molecule developed by ChemT to significantly boost T cell expansion by 5-10 times, while also enhancing the quality of T cell therapy products. This innovation offers a promising solution to some of the biggest challenges in manufacturing T cell therapeutics. Chemplify diverts T cell into a younger and healthier state via novel pathway. This opens a unique opportunity to explore an uncharted mechanism that could reshape our understanding of T cell biology.
Our AI platform has active pipelines in various cell types across different modalities, including small molecules, antibodies, mRNA, etc. We partner with world-leading institutions on the R&D, serve biotechs, pharma, CDMOs and hospitals with world-class assets.
Supported by
Partner with ChemT
We are actively seeking collaboration with key stakeholders in biologics, including research labs, biotech companies, pharmaceutical firms, and leading technology providers.